Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Consolidated Edison, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Consolidated Edison, Inc. trades at $113.37 (market cap $41.64B). The key difference: Consolidated Edison, Inc. is far larger — about 9.3× ACADIA Pharmaceuticals Inc.'s market cap, and Consolidated Edison, Inc. pays a 3.08% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ED | |
|---|---|---|
Market Cap | $4.49B | $41.64B |
Sector | Health | Utilities |
52-Week High | $28.06 | $115.46 |
52-Week Low | $20.06 | $95.37 |
Enterprise Value | $3.69B | $68.67B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Consolidated Edison (ED) trades at $112.99, down 0.88% on the day, with a bullish technical signal from moving averages. The utility company reported mixed Q1 2026 earnings but maintains steady revenue growth and a 12.52% net income margin. Recent news highlights grid upgrades and a new $2 billion equity offering program announced May 8, 2026.
ED offers stable dividend income with a 52-year growth streak but faces analyst caution with 63% hold ratings. Upside potential exists from infrastructure investments, while risks include debt levels and regulatory pressures. The consensus price target of $103.50 suggests limited near-term appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
